Johnson & Johnson Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31)
Johnson & Johnson (JNJ) reported Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) of $840.00 million for the 12-month period ending 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FiniteLivedIntangibleAssetsFutureAmortizationExpense · last filed 2012-02-23
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for the quarter ending 2012-01-01 was $0.00, a 100.00% decline year-over-year.
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for the quarter ending 2011-10-02 was $0.00.
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for the quarter ending 2011-07-03 was $110.00M.
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for the quarter ending 2011-04-03 was $730.00M.
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for fiscal 2012 was $840.00M, a 15.07% increase from fiscal 2011.
- Johnson & Johnson finite-lived intangible assets, future amortization expense (deprecated 2012-01-31) for fiscal 2011 was $730.00M.
| Period end | Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) 3 month | Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) 6 month | Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) 9 month | Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-01-01 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $110.00M derived: sum of 3 quarters · filed 2012-02-23 | $840.00M 10-K · filed 2012-02-23 |
| 2011-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $110.00M derived: sum of 2 quarters · filed 2011-11-08 | $840.00M 10-Q · filed 2011-11-08 | $870.00M derived: sum of 4 quarters · filed 2011-11-08 |
| 2011-07-03 | $110.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $840.00M 10-Q · filed 2011-08-09 | $870.00M derived: sum of 3 quarters · filed 2011-08-09 | $870.00M derived: sum of 4 quarters · filed 2011-08-09 |
| 2011-04-03 | $730.00M 10-Q · filed 2011-05-10 | $760.00M derived: sum of 2 quarters · filed 2011-05-10 | $760.00M derived: sum of 3 quarters · filed 2011-05-10 | |
| 2011-01-02 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $30.00M derived: sum of 2 quarters · filed 2011-02-25 | $730.00M 10-K · filed 2011-02-25 | |
| 2010-10-03 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-10 | $700.00M 10-Q · filed 2010-11-10 | ||
| 2010-07-04 | $700.00M 10-Q · filed 2010-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |